Despite these clinical milestones and ongoing innovation, including first-in-human studies of new oncology drugs, Pfizer Inc.

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Pfizer's attractive valuation and ultra-high dividend yield make it a great pick right now. Pfizer (NYSE: PFE) is a great ...

The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- ...

Pfizer's (NYSE: PFE) management team is confident in its 2025 opportunities. Where to invest $1,000 right now? Our analyst ...

Jim Cramer once confidently backed Pfizer, praising its pipeline and high dividend, forecasting a big post-COVID comeback. “I ...

The highest dividend-paying stocks in the S&P 500 right now are blue-chip stocks that yield anywhere between 6.2% and 9.3% annually. And while markets are largely flat since Jan. 1 — with a ...

We recently published a list of Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a look at ...

The stock's fall snapped a four-day winning streak.

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

A record number of so-called reverse Yankee deals have been sold this year, an early sign of a possible lasting shift in the ...